Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA

December 2015

Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA. It won't just be for COPD anymore.

But don't expect to see it used in too many asthma patients.

Explain that adding Spiriva to a high-dose inhaled steroid PLUS a long-acting beta-agonist (salmeterol, etc) seems to reduce asthma exacerbations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Heart Failure Suggest Entresto for heart failure patients with persistent symptoms
Geriatrics Think of Beers Criteria as a "Warning Light" Rather Than a "Stop Sign"
Opioids More patients will need your help tapering off chronic opioids
Diabetes Diabetes patients will need your help sticking with metformin
Diabetes association between the SGLT2 inhibitor, Invokana (canagliflozin), and bone fractures
Cardiology Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol
Vitamins & Minerals Consider Supplementing Vitamin D in Kids if Diet Isn't Enough
Alcohol when to avoid alcohol with certain medications
Medication Errors Follow the Mantra, "When in Doubt, Fill the Incident Report Out"
Supplements the dangers of using dietary supplements
Asthma Spiriva Respimat (tiotropium) will be the first long-acting anticholinergic for ASTHMA